SALT LAKE CITY & PROVO, Utah & DENVER--(BUSINESS WIRE)--The University of Utah, Brigham Young University and Ceragenix Pharmaceuticals, Inc.(OTCBB:CGXP) today announced that researchers at the University of Utah have selected Ceragenix’s Cerashield™ as the product it plans to test pursuant to grants received from the United States Department of Defense and the Department of Veterans Affairs, Research Rehabilitation and Development to help find ways to reduce infections associated with artificial limbs. Ceragenix’s Cerashield, an investigational antimicrobial wound dressing, is based on technology patented by Brigham Young University and exclusively licensed to Ceragenix. The technology is this year’s winner of the Utah Innovation Award in the field of biotechnology and pharmaceuticals.
